MNX1 antisense RNA 1 (MNX1-AS1)

MNX1 antisense RNA 1 (MNX1-AS1) is a long non-coding RNA (lncRNA) implicated as a competing endogenous RNA in several cancers, including bladder cancer, non-small cell lung cancer, laryngeal squamous cell carcinoma, and others[1][3][4]. MNX1-AS1 is upregulated in multiple tumor types and functions primarily by acting as a molecular sponge for distinct microRNAs, including miR-218-5p and miR-370, thereby modulating the expression of oncogenic drivers such as RAB1A and FoxM1[1][3]. Increased MNX1-AS1 levels are associated with enhanced tumor cell proliferation, migration, invasion, and epithelial-mesenchymal transition, while knockdown leads to reduced oncogenic properties and increased apoptosis in tumor cells[1][3][4]. Its high expression correlates with advanced disease stage, lymph node metastasis, and poor patient prognosis, suggesting value as a potential therapeutic target and biomarker for disease progression[1][3][4]. No approved drugs are known to directly target MNX1-AS1.

Other names

CCAT5LOC645249MAYAMST1/2-antagonizing lncRNA for YAP activation

Acts as a ceRNA, sponging specific miRNAs (e.g., miR-218-5p, miR-370) to control the expression of oncogenic proteins like RAB1A and FoxM1[1][3].